{
    "guideline_id": "2024CSCO胆道恶性肿瘤诊疗指南.txt",
    "cancer_info": {
        "cancer_name": "Biliary Tract Cancer"
    },
    "clinical_recommendations": [
        {
            "clinical_context": "Locally advanced biliary tract cancer",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Gemcitabine plus cisplatin (GP) or gemcitabine plus cisplatin plus nab-paclitaxel",
            "treatment_line": "Neoadjuvant",
            "biomarker_requirements": [],
            "recommendation_level": "Level II Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Postoperative adjuvant therapy for biliary tract cancer",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Capecitabine or tegafur-gimeracil-oteracil (S-1)",
            "treatment_line": "Adjuvant",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Advanced biliary tract cancer, first-line treatment",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Gemcitabine plus cisplatin plus durvalumab or pembrolizumab",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Advanced biliary tract cancer with MSI-H/dMMR",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Pembrolizumab",
            "treatment_line": "First-line or second-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "MSI-H/dMMR",
                    "status": "Positive",
                    "testing_guidance": ""
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Advanced biliary tract cancer, second-line treatment",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "mFOLFOX",
            "treatment_line": "Second-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Advanced intrahepatic cholangiocarcinoma with FGFR2 fusion, second-line treatment",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Pemigatinib or futibatinib",
            "treatment_line": "Second-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "FGFR2 fusion",
                    "status": "Positive",
                    "testing_guidance": ""
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Advanced intrahepatic cholangiocarcinoma with IDH1 mutation, second-line treatment",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Ivosidenib",
            "treatment_line": "Second-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "IDH1 mutation",
                    "status": "Positive",
                    "testing_guidance": ""
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Advanced biliary tract cancer with BRAF V600E mutation, second-line treatment",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Dabrafenib plus trametinib",
            "treatment_line": "Second-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "BRAF V600E",
                    "status": "Positive",
                    "testing_guidance": ""
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Advanced biliary tract cancer with HER2 positive, later-line treatment",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Trastuzumab deruxtecan",
            "treatment_line": "Later-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "HER2",
                    "status": "Positive",
                    "testing_guidance": ""
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "MSI-H/dMMR predicts response to immunotherapy; FGFR2 fusion predicts response to FGFR inhibitors; IDH1 mutation predicts response to IDH1 inhibitors; BRAF V600E mutation predicts response to BRAF/MEK inhibitors; HER2 amplification predicts response to HER2-targeted therapy."
    },
    "tcm_recommendations": []
}